enGene Holdings

ENGN

Market cap $310M

Overview Fund Activity

6.52 USD

+0.45

7.41%

At close Updated Sep 17, 4:00 PM EDT

1 day

7.41%

5 days

3.49%

1 month

75.27%

3 months

100.62%

6 months

27.1%

Year to date

-7.65%

1 year

-6.05%

5 years

-67.4%

10 years

-67.4%

About: enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Employees: 57

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

19% more funds holding

Funds holding: 31 [Q1] → 37 (+6) [Q2]

1.22% less ownership

Funds ownership: 80.31% [Q1] → 79.09% (-1.22%) [Q2]

20% less capital invested

Capital invested by funds: $183M [Q1] → $147M (-$36.3M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

56% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 9

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

176% upside

Avg. target

$22

230% upside

High target

$25

283% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley Jeffrey Hung	$18	Overweight Maintained	12 Sep 2025
HC Wainwright & Co. Andres Y. Maldonado	$25	Buy Reiterated	12 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ENGN published over the past 30 days

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. “Reaching target enrollment in LEGEND's pivotal Cohort 1 and securing RMAT designation are important milestones that mark our continued momentum,” said Ron Cooper, Chief Executive Officer of enGene. “We look forward to providing a data.

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

enGene Holdings Inc. (NASDAQ:ENGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Ronald H. Cooper - President, CEO & Director Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Welcome to the session of the Morgan Stanley Global Healthcare Conference.

EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid (“detalimogene” and previously EG-70) in patients with high-risk, non-muscle invasive bladder cancer (NMIBC). LEGEND's pivotal Cohort 1 is studying detalimo.

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral gene therapy company, today announced that management will participate in the following investor conferences in September: 2025 Wells Fargo Healthcare Conference Date: Wednesday, September 3, 2025 Time: 8:45 a.m. ET H.C. Wainwright 27th Annual Global Investment Conference Date: Monday, September 8, 2025 Time: 1:30 p.m. ET Morgan Stanley 23rd Annual Global Healthcare Conference Date:.

enGene to Participate in Upcoming Investor Conferences

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today reported the grant of inducement equity awards to three newly-hired employees, with a grant date of July 31, 2025. The inducement awards consist of non-qualified stock options to purchase an aggregate 93,200 of the Company's common shares. The options each have an exercise price of $3.79 per share, which is equal to the closing p.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene's strategic transition toward planned commerci.

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company's lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive,.

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, ENGN maintains a cash runway into 2027, supporting ongoing development without major liquidity concerns in the near term. While regulatory discussions are encouraging, the investment thesis hinges on positive LEGEND trial results, making this a high-risk, high-reward scenario.

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Amy Pott, Chief Global Commercialization Officer, with a grant date of June 16, 2025. The inducement award for Ms. Pott consists of a non-qualified stock option to purchase an aggregate 400,000 of the Company's common shares. The inducement awards fo.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. “We have seen strong enrollment in the pivotal cohort of our LEGEND study,” said Ron Cooper, Chief Executive Officer of enGene. “This positions us to stay on track for our planned trial updates across all cohorts in the second.

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

See News Rankings

Charts implemented using Lightweight Charts™